Vidcast: https://www.instagram.com/p/DdVfxNKh-3Y/

A new study suggests that popular GLP-1 drugs such as Ozempic, Wegovy and Zepbound may be linked to a higher risk of male-pattern hair loss in men who are already genetically susceptible.

NYU dermatologists analyzed genetic data tabulating both GLP-1 receptor activity and androgenetic alopecia, that is hair loss. They found that genetically predicted higher GLP-1 receptor activity was associated with about a 7 percent higher risk of male-pattern hair loss. The association remained after accounting for hypertension, insulin resistance and lower testosterone.

Interesting result, but the study only pinpoints an association. The researchers did not actually follow men taking Ozempic or Wegovy and measure any resultant hair loss. They used an inherited genetic variation in the GLP-1 receptor gene as a proxy for increased GLP-1 activity.

*However, where there is smoke, there may be fire. Hair shedding has already been reported by GLP-1 users but is often attributed to rapid weight loss. This study raises the possibility that GLP-1 signaling itself may be the cause. Future studies are needed to determine the exact mechanism, which men are at risk, and whether the same relationship exists in women.

References on my website.

#Ozempic #Wegovy #GLP1 #HairLoss #MedicalResearch